Guess which ASX All Ords share is crashing 30% today

Investors have been hitting the sell button in a panic on Friday.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Integral Diagnostics Ltd (ASX: IDX) share price is having a day to forget on Friday.

At the time of writing, the ASX All Ords share is down 30% to $1.86.

A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.

Image source: Getty Images

Why is this ASX All Ords share crashing?

Investors have been scrambling to the exits today after the medical imaging services provider released a very disappointing trading update.

According to the release, first-quarter revenue growth of 8.4% was achieved in Australia compared with the prior corresponding period.

As a comparison, management highlights that Medicare benefits for the states in which Integral Diagnostics operates have seen a 9.5% increase in the weighted average benefits paid, adjusted for working days.

Over in New Zealand, the company achieved a 4.1% increase in constant currency revenue compared with the prior corresponding period.

However, this growth appears to have been offset by higher-than-expected labour costs which have impacted its operating EBITDA. This has been driven by clinical staff shortages, particularly in regional areas, and cost inflation.

In light of this, the ASX All Ords share has not seen the expected operating EBITDA margin improvement it was expecting.

Management advised that it is responding to these pressures by accelerating productivity and efficiency initiatives. These actions are expected to lead to an improvement in its margin performance in the second half.

The company hasn't provided any earnings guidance for the half (or full year) but has given investors an idea of what to expect in respect to capex, depreciation, and finance costs.

Replacement and growth capex is to be in the range of $30 million to $40 million in FY 2024. Whereas depreciation of ~$45 million and finance costs of ~$22 million are forecast for the 12 months. The latter assumes that the Reserve Bank will increase rates by a further 0.25% next week.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Integral Diagnostics. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Five healthcare workers standing together and smiling.
Healthcare Shares

3 ASX 200 healthcare shares to buy amid sector rout

The experts are backing these stocks for price growth.

Read more »

Researchers and doctors with futuristic 3D hologram overlay for body anatomy or DNA in hospital clinic.
Healthcare Shares

Are investors taking a big gamble chasing 4DX shares higher and higher?

Investor interest in this ASX healthcare tech stock is booming.

Read more »

A group of people in a corporate setting do a collective high five.
Broker Notes

3 reasons to buy Ramsay Health Care shares today

A leading analyst expects Ramsay Health Care shares to keep outperforming in the months ahead.

Read more »

Half a man's face from the nose up peers over a table.
Healthcare Shares

If I could buy only 1 ASX 200 share right now, it would be…

This stock looks underpriced and oversold to me.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

CSL shares slide again in March — but is a comeback brewing?

Brokers remain upbeat and see upside up to 95% for the biotech stock.

Read more »

A female athlete in green spandex leaps from one cliff edge to another representing 3 ASX shares that are destined to rise and be great
Broker Notes

Up 57% since February, why Telix shares could keep leaping higher in 2026

A leading analyst believes investors are undervaluing Telix shares. But why?

Read more »

A woman has a thoughtful look on her face as she studies a fan of Australian 20 dollar bills she is holding on one hand while he rest her other hand on her chin in thought.
Healthcare Shares

Is it time to get greedy with CSL shares?

This ASX healthcare giant is out of favour, but that may be where opportunity starts.

Read more »

Stressed, unhappy, and tired scientist with a headache working on a computer in a lab.
Healthcare Shares

3 ASX 200 healthcare shares at multi-year lows

Does this present a buying opportunity?

Read more »